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Psychotic disorders affect about 3% of the population worldwide and are associated with high 
personal, social and economic costs. They tend to have their first onset in adolescence. Increasing 
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emphasis has been placed on early intervention to detect illness and minimise disability. In the late 
1990s criteria were developed to identify individuals at high risk for psychotic disorder. These are 
known as the At Risk Mental State (ARMS) criteria. While ARMS individuals have a risk of psychosis 
much greater than the general population, most individuals meeting the ARMS criteria will not 
develop psychosis. Despite this, the National Institute for Health and Care Excellence recommends 
cognitive behavioural therapy (CBT) for all ARMS people.  
Clinical prediction models that combine multiple patient characteristics to predict individual outcome 
risk may facilitate identification of patients who would benefit from CBT, and conversely those that 
would benefit from less costly and less intensive regular mental state monitoring. The study will 
systematically review the evidence on clinical prediction models aimed at making individualised 
predictions for the transition to psychosis. The review has been registered with PROSPERO 
(CRD42018108488). 
Methods 
Database searches will be conducted on PsycINFO, Medline, EMBASE and CINAHL. Reference lists and 
subject experts will be utilised. No language restrictions will be placed on publications but searches 
will be restricted to 1994 onwards; the initial year of the first prospective study using ARMS criteria. 
Studies of any design will be included if they examined, in ARMS patients, whether more than one 
factor in combination is associated with the risk of transition to psychosis. Study quality will be 
assessed using the prediction model risk of bias assessment tool (PROBAST). Clinical prediction models 
will be summarised qualitatively and, if tested in multiple validation studies, their predictive 
performance will be summarised using a random-effects meta-analysis model. 
Discussion 
The results of the review will identify prediction models for the risk of transition to psychosis. These 
will be informative for clinicians currently treating ARMS patients and considering potential preventive 
interventions. The conclusions of the review will also inform the possible update and external 
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validation of prediction models and clinical prediction rules to identify those at high or low risk of 
transition to psychosis. 
Keywords 
Prediction, risk factors, ARMS, psychosis, meta-analysis 
Background 
Identification of individuals at high and imminent risk of developing a first episode of psychosis is 
possible through use of the "At Risk Mental State" (ARMS) criteria (1, 2), a set of criteria suggestive of 
high-risk for psychosis originally proposed by Yung and operationally defined as low-grade “psychotic-
like symptoms” that cause distress.(3) Meta-analytic evidence indicates that about 15-22% of ARMS 
individuals develop psychosis within 12 months from ARMS assessment.(4, 5) Identification of ARMS 
individuals therefore presents the opportunity for early intervention to prevent the onset of psychosis. 
However, most individuals meeting the ARMS criteria will not develop psychosis. This means that 
some ARMS individuals might be receiving unnecessary treatment and that the health services may 
be using a costly interventions (preventive interventions with a growing evidence-base e.g. Cognitive 
Behaviour Therapy; CBT) in people who may not need it. Furthermore, growing calls for improving the 
routine clinical management of people with ARMS (e.g. the UK’s Early Intervention Access and Waiting 
Standards, which now require all Early Intervention in Psychosis Services to assess, monitor and 
manage ARMS individuals (6)) are likely to result in an additional strain on resources, and an urgent 
need to develop better systems to identify ARMS individuals that might be at the highest risk of 
developing psychosis and might therefore particularly benefit from receiving evidence-based 
preventive interventions.  
Alternative indicators for assessing risk of transitioning to psychosis do exist, such as basic 
symptoms.(7)  Prediction of risk in this way is comparable, or in some cases slightly superior than 
predicting transition to psychosis using ARMS.(4) However, ARMS is the most widely used approach  
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to define the psychosis prodrome worldwide and forms part of national clinical assessment in the 
UK.(6)  Indeed, ARMS is a standard approach within the UK with the whole workforce being trained in 
the assessment of ARMS.  Consequently, there are specific calls around prediction of first episode 
psychosis focussing specifically on ARMS.(4, 8) 
Prognostic factors identify groups of patients at highest risk and thus inform treatment decision 
making, patient counselling and policies.(9) Clinical prediction models combine multiple prognostic 
factors to predict individual outcome risk for individuals. Research to better stratify ARMS patients 
according to levels of risk of psychosis could facilitate more efficient use of resources available to 
health services. For example, those predicted to be at highest risk could be offered CBT, while lower 
risk patients could be offered less costly and less intensive regular mental state monitoring. In this 
way a clinical prediction tool that can be used in routine practice could lead to the development of 
more cost-effective pathways and management plans. 
Two recent systematic reviews summarised existing prediction models for ARMS patients.(10, 11) 
Both systematic reviews were undertaken in 2017 and since then many additional relevant prediction 
models have been published.  Additionally the Prediction Study Risk of Bias Assessment Tool 
(PROBAST) guidelines were published in 2019.(12)  These facilitate thorough assessment of risk of bias 
of prediction model studies.  Therefore this systematic review is both timely and necessary. 
Our work aims to systematically review all the evidence for current prediction models for transition 
to psychosis in individuals meeting the ARMS criteria. The findings should inform clinical practice and 
patient care by identifying demographic and clinical characteristics that show consistent evidence of 
predictive value when adjusted for other prognostic factors, and by summarising the current 
prediction models and their predictive performance. It will also inform further research of prognostic 





The aim of this systematic review is to identify and summarise prediction models and clinical decision 
rules predicting transition to (first episode of) psychosis at 12-months, irrespective of whether an 
individual received an intervention or not, in people who have undergone an ARMS assessment in any 
clinical setting.  This systematic review will identify and summarise studies of any prospective or 
retrospective design which utilise multiple prognostic factors in combination to predict the 




The review will include any prospective or retrospective studies (i.e. cohort studies as well as 
randomised controlled trials of preventive interventions), with participants meeting the ARMS criteria, 
which have developed, compared or validated a prediction model, or clinical prediction rule based on 
a model, combining multiple prognostic factors to predict the risk of transition to psychosis. 
Patient group 
This review will include individuals meeting ARMS criteria (also called Ultra High Risk (UHR) or Clinical 
High Risk (CHR) criteria). These are defined as 1) attenuated psychotic symptoms, 2) full-blown 
intermittent psychotic symptoms and 3) genetic/familial risk for schizophrenia in conjunction with a 
significant decrease in functioning and operationalised using suitable measures such as the 
Comprehensive Assessment of At-Risk Mental States (CAARMS) (13) or the Structured Interview for 
Prodromal Syndromes (SIPS) (14). Other prodromal signs/symptoms distinct from ARMS (e.g. basic 
symptoms) will not be included. Studies with mixed populations, including those outside of the remit, 
will be included provided that the appropriate data for our defined group of patients is extractable. 
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Eligible prediction models will include patients at risk of transitioning to psychosis, and thus recruited 
to the study at the time of the ARMS assessment.  There are no groups of ARMS individual for which 
any clinical prediction model predicting transition to psychosis cannot be used.  
Setting 
Studies in any setting will be included. 
Potential prediction models 
Studies must report a clinical prediction model utilising multiple prognostic factors to predict the risk 
of transition to psychosis following confirmation that a patient meets the ARMS criteria. 
Primary and secondary outcomes of our review 
The primary outcome for the review will be the predictive accuracy of prediction models in relation to 
psychosis transition at 12 months, defined using standard diagnostic classification systems (DSM-III, 
DSM-IV, DSM-5, ICD-10, ICD-11) or commonly used ARMS assessment schedules (e.g. CAARMS or 
SIPS).  The first 12 months is the highest risk period for psychosis onset (15) and the time when 
individuals are most distressed (16) and most likely to engage with services. 
Secondary outcomes will be their predictive accuracy in relation to transition at other time points, 
quality of the developed models in terms of use of appropriate statistical methodology, and the 
feasibility of using the model in clinical practice. 
Search strategy 
Database searches will be conducted on PsycINFO, Medline, EMBASE and CINAHL. No restriction will 
be placed on language of publication but the searches will be restricted to 1994 onward, the initial 
year of the first prospective study using ARMS criteria.(17) No language restriction will be placed on 
the searches. Searches will use index terms and text words that encompass the patient group 




Database searches will be supplemented by: 
1. Inspection of studies included in previous systematic reviews and meta-analyses of psychosis 
transition studies; 
2. Inspection of reference lists of psychosis transition studies identified through the database 
searches; 
3. Inspection of citations of psychosis transition studies identified through the database 
searches. 
Study selection 
Titles and abstracts will be screened for relevance by two reviewers independently using pre-defined 
screening criteria. The screening criteria are broad and consider whether studies included patients 
meeting the ARMS criteria and developed or examined prediction models in relation to transition to 
psychosis. Full texts of any potentially relevant articles will then be obtained and two reviewers will 
independently assess the studies against the full inclusion criteria. When required, additional 
information to ascertain eligibility will be requested from study authors. Discrepancies in selection 
decisions will be discussed, and arbitration by another member of the research team sought to resolve 
such discrepancies. 
Non-English studies will be translated where necessary to facilitate interpretation and data extraction. 
The study selection process will be documented using the PRISMA flow diagram.(18) EndNote 
reference management software will be used to record reviewer decisions, including reasons for 
exclusion.(19) 
Data extraction 
Data will be extracted by two reviewers independently using an in-depth piloted data extraction form. 
Disagreements will be resolved through discussion or referral to a third reviewer   The data extraction 
form will be pilot tested using a representative 5% sample of the studies to be reviewed.  Consensus 
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between review authors will be gained before any modifications are made to the form.  If major 
changes are needed after the first testing, the pilot testing will be repeated on a new set of 5% of the 
studies. Data extraction will consider study characteristics, study design characteristics, patient 
characteristics, candidate prognostic factors considered including information on missing data, 
outcome measures, statistical methods employed and how prognostic factors included in the analysis 
were handled, and prediction model information. Data extraction specifically related to clinical 
prediction models will include the final model (its specification, included factors, values of regression 
coefficients and standard errors), how it was developed, and any internal or external validation 
performance statistics for discrimination (such as the c-statistics or area under the curve) or for 
calibration (such as the expected/observed events ratio), together with their associated measures of 
spread. This will be informed by the Critical Appraisal and Data Extraction for Systematic Reviews of 
Prediction Modelling Studies (CHARMS) checklist which helps frame the review question, design the 
review, and extract the relevant items from the reports of the primary prediction modelling studies.  
Assessment of study quality 
The risk of bias (quality) of any studies developing or evaluating a prediction model will be assessed 
using the criteria described by Altman (20) and by PROBAST.(12) PROBAST involves assessment of 
participants, predictors, outcome and analysis. 
Evidence synthesis 
Any studies reporting the development of a prediction model will be summarised narratively, in 
particular what prognostic factors were included in the final model, how the included variables were 
coded, what the specification of the model was and how it produces an individual outcome probability 
or risk score, the reported predictive accuracy of the model, and whether the model was validated 
internally and/or externally, and if so how. 
If multiple studies are found that externally validate the same prediction model, then calibration 
statistics (such as expected/observed events) and discriminatory statistics (such as the c-statistic or 
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area under the curve) will be synthesised using random-effects meta-analysis methodology of Debray 
and Snell (21, 22) to summarise the model’s average performance across different settings and its 
predicted performance in a future setting.  If there are updated versions of the same prediction model 
identified in our review then only statistics for the most recent model will be included in the meta-
analysis. 
If we identify multiple prediction models that have been adequately externally validated, we will 
compare their performance narratively, taking into account the different case mix, how this relates to 
our own setting, and also the quality of studies. 
Analysis of subgroups or subsets 
If there are sufficient relevant prediction models available, subgroup analyses will synthesise 
calibration and discrimination statistics for studies conducted in different settings (countries) or 
different types of studies (prospective studies vs randomised studies vs randomised trials) or different 
model types (logistic vs survival analysis). 
Discussion 
The results of our systematic review of existing studies have the potential to inform clinical 
management of patients diagnosed as ARMS. In particular, the results of the review will identify 
clinical prediction models for the risk of transition to psychosis after diagnosis. These will be 
informative for clinicians currently treating patients and considering whether to prescribe preventive 
interventions for psychosis or not for particular individuals. The review will also identify areas where 
the evidence for or against particular candidate prediction models is lacking, and this will lead to 
recommendations for initiating additional prediction model development and validation. 
The models identified by this review as being potentially informative when estimating risk of transition 
to psychosis will be considered in related research by the authors (UK National Institute for Health 
Research HTA Project 17/31/05). This related project aims to update (via recalibration and extension 
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to include new predictors as necessary) and externally validate any relevant existing prediction models 
or clinical prediction rules to identify a sub-group of patients at low risk of transition (in whom it is 
considered safe to undergo regular mental state monitoring) and in contrast to identify a sub-group 
of patients at high risk of transition to psychosis. Therefore, our systematic review is a crucial step 
towards the evidence-based use of prognostic factors and risk prediction in patients with ARMS 
considering treatment. 
Appendix 1 
Medline search strategy: 
1. (ARMS or at risk mental state).ti,ab. 
2. Basic symptoms.ti,ab. 
3. Prodromal psychosis.ti,ab. 
4. Psychosis risk.ti,ab. 
5. (UHR or ultra high risk or CHR or clinical high risk).ti,ab. 
6. Prodrom*.ti,ab. 
7. Psychosis*.ti,ab. 
8. 6 and 7 
9. 1 and 7 
10. 5 and 7 
11. 1 or 2 or 3 or 4 or 5 or 8 or 9 or 10 
12. (transition or transition$).ti,ab. 
13. exp "Predictive Value of Tests"/ 
14. predict$.ti,ab. 
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